Scarica l'app Stockscreener
4.08
6.45%
0.28
Dopo l'orario di chiusura:
3.90
-0.18
-4.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Precedente Chiudi:
$3.80
Aprire:
$3.76
Volume 24 ore:
269.62K
Relative Volume:
0.57
Capitalizzazione di mercato:
$37.02M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
-5.5135
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
-0.86%
1M Prestazione:
-47.87%
6M Prestazione:
-67.55%
1 anno Prestazione:
-87.96%
Intervallo 1D:
$3.72
$4.08
Intervallo di 1 settimana:
$3.56
$4.13
Portata 52W:
$3.56
$34.80
Bluebird Bio Inc Stock (BLUE) Company Profile
Nome
Bluebird Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Confronta BLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.08 | 37.02M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Downgrade | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-19 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Iniziato | JP Morgan | Overweight |
| 2023-03-07 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Reiterato | Barclays | Equal Weight |
| 2021-11-08 | Reiterato | Canaccord Genuity | Hold |
| 2021-11-08 | Downgrade | Goldman | Neutral → Sell |
| 2021-11-08 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Reiterato | Wedbush | Neutral |
| 2021-11-08 | Reiterato | Wells Fargo | Equal Weight |
| 2021-08-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Ripresa | William Blair | Mkt Perform |
| 2021-08-09 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Downgrade | Berenberg | Buy → Hold |
| 2021-03-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-02-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-02-16 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Downgrade | Stifel | Buy → Hold |
| 2020-11-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Iniziato | Mizuho | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-27 | Aggiornamento | Stifel | Hold → Buy |
| 2020-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Ripresa | BofA/Merrill | Buy |
| 2020-02-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-10-01 | Iniziato | Stifel | Hold |
| 2019-08-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Aggiornamento | Maxim Group | Hold → Buy |
Mostra tutto
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
Turbulence at the FDA & bluebird Bio’s sale - STAT
bluebird bio stock slides for second day on buyout news - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com Nigeria
Bluebird bio stock plunges to 52-week low of $4.89 amid challenges - Investing.com Nigeria
Latham & Watkins Advises bluebird bio in Acquisition by Carlyle and SK Capital - Latham & Watkins LLP
Investment firms Carlyle and SK Capital to acquire gene therapy developer bluebird bio - BioProcess Insider
BofA moves to No Rating on Bluebird Bio after deal announcement - TipRanks
Dow Tumbles Over 700 Points; US Services PMI Falls In February - Benzinga
bluebird bio Sale to Carlyle and SK Capital Partners - Leerink Partners
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones - TipRanks
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch -February 21, 2025 at 08:14 am EST - Marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc.BLUE - PR Newswire
Struggling bluebird bio to go private for less than $30m - Pharmaceutical Technology
Cheap-cheap? Bluebird dodges bankruptcy with $30M buyout - BioWorld Online
Bluebird bio Agrees to be Acquired by Carlyle Group, SK Capital Partners; Shares Fall Sharply - Marketscreener.com
Bluebird bio to sell to investment funds after struggling to make money from gene therapies - Endpoints News
SK Capital Partners, LP and The Carlyle Group Inc. (NasdaqGS:CG) entered into an agreemet to acquire bluebird bio, Inc. - Marketscreener.com
Cash-strapped bluebird bio to be sold for less than $30M upfront - FirstWord Pharma
Once valued at $10B, bluebird bio sold to private equity firms for $29M - FiercePharma
Bluebird, at risk of default, agrees to take-private deal - BioPharma Dive
Once a darling of biotech, bluebird sells for less than $30M upfront - The Business Journals
Carlyle and SK Capital take bluebird bio private in $477m deal - Private Equity Insights
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - KFGO
An awkward moment for Pfizer’s Bourla in Washington - STAT
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M - BioSpace
Bluebird Bio downgraded to Neutral from Outperform at Baird - TipRanks
Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital - Marketscreener.com
Bluebird Bio Inc Azioni (BLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bluebird Bio Inc Azioni (BLUE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Colvin Richard A | Chief Medical Officer |
Feb 03 '25 |
Sale |
7.39 |
64 |
473 |
8,194 |
| Vittiglio Joseph | Chief Business & Legal Officer |
Feb 03 '25 |
Sale |
7.39 |
238 |
1,759 |
4,501 |
| Obenshain Andrew | President and CEO |
Feb 03 '25 |
Sale |
7.39 |
86 |
636 |
18,485 |
2.95%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):